Discoveries, drugs and skeletal disorders

被引:137
作者
Goltzman, D
机构
[1] McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada
[2] McGill Univ, Ctr Hlth, Montreal, PQ H3A 1A1, Canada
关键词
D O I
10.1038/nrd916
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Bone turnover, in which cells of the osteoclast lineage resorb bone and cells of the osteoblast lineage deposit bone, normally occurs in a highly regulated manner throughout life. Perturbations to these processes underlie skeletal disorders, such as osteoporosis, which are common, chronic and disabling, and increase with age. On the basis of empirical observations or on understanding of the endocrinology of the skeleton, excellent bone-resorption inhibitors, but few anabolic agents, have been developed as therapeutics for skeletal disorders. However, powerful new genomic and genetic tools are uncovering new loci that regulate the activity of both osteoclasts and osteoblasts, and these hold great promise for future drug development.
引用
收藏
页码:784 / 796
页数:13
相关论文
共 121 条
[31]   Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene -: Results from a 3-year randomized clinical trial [J].
Ettinger, B ;
Black, DM ;
Mitlak, BH ;
Knickerbocker, RK ;
Nickelsen, T ;
Genant, HK ;
Christiansen, C ;
Delmas, PD ;
Zanchetta, JR ;
Stakkestad, J ;
Glüer, CC ;
Krueger, K ;
Cohen, FJ ;
Eckert, S ;
Ensrud, KE ;
Avioli, LV ;
Lips, P ;
Cummings, SR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (07) :637-645
[32]   The role of statins as potential targets for bone formation [J].
Garrett, IR ;
Mundy, GR .
ARTHRITIS RESEARCH, 2002, 4 (04) :237-240
[33]  
Gazit D, 1998, J CELL BIOCHEM, V70, P478, DOI 10.1002/(SICI)1097-4644(19980915)70:4<478::AID-JCB5>3.0.CO
[34]  
2-G
[35]   Destructive periodontitis lesions are determined by the nature of the lymphocytic response [J].
Gemmell, E ;
Yamazaki, K ;
Seymour, GJ .
CRITICAL REVIEWS IN ORAL BIOLOGY & MEDICINE, 2002, 13 (01) :17-34
[36]   Cyclic administration of pamidronate in children with severe osteogenesis imperfecta [J].
Glorieux, FH ;
Bishop, NJ ;
Plotkin, H ;
Chabot, G ;
Lanoue, G ;
Travers, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (14) :947-952
[37]  
Goltzman David, 2000, Cancer, V88, P2903, DOI 10.1002/1097-0142(20000615)88:12+<2903::AID-CNCR4>3.0.CO
[38]  
2-G
[39]   LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development [J].
Gong, YQ ;
Slee, RB ;
Fukai, N ;
Rawadi, G ;
Roman-Roman, S ;
Reginato, AM ;
Wang, HW ;
Cundy, T ;
Glorieux, FH ;
Lev, D ;
Zacharin, M ;
Oexle, K ;
Marcelino, J ;
Suwairi, W ;
Heeger, S ;
Sabatakos, G ;
Apte, S ;
Adkins, WN ;
Allgrove, J ;
Arslan-Kirchner, M ;
Batch, JA ;
Beighton, P ;
Black, GCM ;
Boles, RG ;
Boon, LM ;
Borrone, C ;
Brunner, HG ;
Carle, GF ;
Dallapiccola, B ;
De Paepe, A ;
Floege, B ;
Halfhide, ML ;
Hall, B ;
Hennekam, RC ;
Hirose, T ;
Jans, A ;
Jüppner, H ;
Kim, CA ;
Keppler-Noreuil, K ;
Kohlschuetter, A ;
LaCombe, D ;
Lambert, M ;
Lemyre, E ;
Letteboer, T ;
Peltonen, L ;
Ramesar, RS ;
Romanengo, M ;
Somer, H ;
Steichen-Gersdorf, E ;
Steinmann, B .
CELL, 2001, 107 (04) :513-523
[40]   C-FOS - A KEY REGULATOR OF OSTEOCLAST-MACROPHAGE LINEAGE DETERMINATION AND BONE REMODELING [J].
GRIGORIADIS, AE ;
WANG, ZQ ;
CECCHINI, MG ;
HOFSTETTER, W ;
FELIX, R ;
FLEISCH, HA ;
WAGNER, EF .
SCIENCE, 1994, 266 (5184) :443-448